Alkermes is transitioning from Vivitrol-driven legacy revenues toward a Lumryz-led sleep platform, with an $8.59% probability-weighted annualized return and substantial alixorexton upside offset by execution and leverage risks.
Overview
Alkermes is a fully integrated biopharmaceutical company focused on neuroscience and sleep medicine, combining a proprietary product portfolio with recurring contract manufacturing and royalty cash flows. Proprietary products generated 83% of Q2 2026 revenue and include Vivitrol, Aristada, Lybalvi, and the newly acquired Lumryz; royalties and manufacturing contributed 17%. **Q2 2026 revenue rose 27.0% to $496.0 million**, exceeding consensus estimates of $454.0 million to $457.4 million, while proprietary sales increased 34.0% to $411.7 million. Lumryz produced $96.6 million in its first reported quarter, and Lybalvi grew 11.5% to $94.0 million, partially offsetting Aristada’s 4.5% decline to $96.7 million. GAAP earnings were temporarily compressed to $0.5 million by acquisition-related charges, but Adjusted EBITDA increased 10.0% to $139.2 million. The investment case hinges on Lumryz’s once-nightly advantage, a potential March 2028 IH launch, and alixorexton Phase 3 progress, while Vivitrol faces Teva generic entry on January 15, 2027. At approximately $49.81, valuation is 4.4x 2026 estimated sales and about 16x EV/Adjusted EBITDA. Near-term catalysts include Lumryz adoption, debt reduction, Brilliance enrollment and data, and the IH regulatory process.